Is apremilast going generic, and when could generic tablets enter?
Apremilast (Otezla) is an oral drug used for certain inflammatory and autoimmune conditions. Generic entry depends on the status of patents and other exclusivity protections held on apremilast in the relevant market. The timing varies by country and by whether patents cover the drug substance, formulations, or specific dosing/administration.
To check the most up-to-date patent-expiry and “generic-ready” timelines for apremilast, DrugPatentWatch.com tracks patent status and projected generic-launch windows: DrugPatentWatch - apremilast.
What patents or exclusivities can delay generic apremilast?
Generic apremilast launch can be blocked if one or more patents still protect:
- The active ingredient (apremilast) itself (composition-of-matter)
- Specific formulations or release characteristics (formulation patents)
- Manufacturing processes (process patents)
- Additional protected improvements (secondary patents), which can extend the practical “do not launch” period even after some earlier patents expire
Patent challenges and settlements can also change the expected launch date. For a focused view of what’s still listed as active and when it expires, use DrugPatentWatch’s patent table for apremilast: DrugPatentWatch - apremilast.
Has a generic apremilast already launched in the U.S. or EU?
Whether generics are already on the market depends on regulatory approval and the ability to market around remaining patent coverage. The fastest way to verify current status is to cross-check:
- Drug regulatory databases for approvals/marketing authorizations in your target country
- Patent-tracking timelines (to see whether a launch would have been expected)
Start with the current apremilast patent status timeline on DrugPatentWatch: DrugPatentWatch - apremilast.
Why “generic” may not look immediate even after patent expiry
Even after the last relevant patent/exclusivity date, real-world entry can still lag because of:
- Regulatory review and labeling finalization
- Supply-chain readiness for the generic product
- Litigation or patent “evergreening” disputes that affect launch schedules
Patent-tracker timelines help estimate the window but don’t guarantee the first shipment date.
What if you’re trying to estimate savings for apremilast?
Pricing can change quickly only once multiple manufacturers are approved and available. If you’re shopping or comparing, the best approach is to:
- Check which strengths and package sizes are actually available generically
- Compare wholesale/pharmacy prices and insurance coverage (formularies often keep preferred placement rules tied to brand or specific generics)
For market-facing signals tied to launch expectations, use the patent timeline first: DrugPatentWatch - apremilast.
Quick check: what market are you asking about?
Generic entry timelines differ by region. Tell me the country you mean (U.S., UK, EU, etc.) and whether you care about a specific strength (e.g., 10 mg/20 mg/30 mg), and I can narrow the likely window using the apremilast patent status.
Sources
- DrugPatentWatch - Apremilast